Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.70 |
| ▸ | GAA | P10253 | 1/20 | 0.70 |
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.59 |
| ▸ | TLR4 | O00206 | 1/20 | 0.58 |
| ▸ | CTSL | P07711 | 1/20 | 0.56 |
| ▸ | CTSB | P07858 | 1/20 | 0.56 |
| ▸ | CTSK | P43235 | 1/20 | 0.56 |
| ▸ | DPP4 | P27487 | 3/20 | 0.54 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
| ▸ | CPB1 | P15086 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | ACHE | P22303 | 1/20 | 0.51 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.51 |
| ▸ | KDM1A | O60341 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28879466 | 0.94 | EPHX1 (0.64) | ALDH1A1GAATSHREPHX1TLR4 | |
| SCHEMBL29492533 | 0.90 | EPHX1 (0.68) | ALDH1A1GAATSHREPHX1TLR4 | |
| SCHEMBL5442669 | 0.90 | EPHX1 (0.68) | ALDH1A1GAATSHREPHX1TLR4 | |
| SCHEMBL5442666 | 0.90 | EPHX1 (0.68) | ALDH1A1GAATSHREPHX1TLR4 | |
| SCHEMBL5442663 | 0.90 | EPHX1 (0.68) | ALDH1A1GAATSHREPHX1TLR4 | |
| SCHEMBL3948456 | 0.89 | ALDH1A1 (0.85) | ALDH1A1GAATSHREPHX1TLR4 | |
| SCHEMBL381922 | 0.89 | ALDH1A1 (0.85) | ALDH1A1GAATSHREPHX1TLR4 | |
| SCHEMBL3948461 | 0.89 | ALDH1A1 (0.85) | ALDH1A1GAATSHREPHX1TLR4 | |
| SCHEMBL3538525 | 0.89 | ALDH1A1 (0.67) | ALDH1A1GAATSHREPHX1TLR4 | |
| SCHEMBL18623681 | 0.89 | ALDH1A1 (0.67) | ALDH1A1GAATSHREPHX1TLR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230097422-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHOD OF THEIR USE | JANSSEN PHARMACEUTICA NV (BE) | 2023-03-30 | — | — | US | disclosed |
| US-11319329-B2 | Inhibitors of Bruton's tyrosine kinase and methods of their use | JANSSEN PHARMACEUTICA NV (BE) | 2022-05-03 | — | — | US | disclosed |
| US-20210101910-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHODS OF THEIR USE | JANSSEN PHARMACEUTICA NV (BE) | 2021-04-08 | — | — | US | disclosed |
| US-10934310-B2 | Inhibitors of Bruton's tyrosine kinase and method of their use | JANSSEN PHARMACEUTICA NV (BE) | 2021-03-02 | — | — | US | disclosed |
| EP-3719022-A1 | POLYCYCLIC COMPOUNDS AS INHIBITORS OF BRUTON'S TYROSINE KINASE | Janssen Pharmaceutica NV (BE) | 2020-10-07 | — | — | EP | disclosed |
| US-10717745-B2 | Inhibitors of Bruton's tyrosine kinase and method of their use | JANSSEN PHARMACEUTICA NV (BE) | 2020-07-21 | — | — | US | disclosed |
| EP-3386991-B1 | POLYCYCLIC COMPOUNDS AS INHIBITORS OF BRUTON'S TYROSINE KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2020-06-03 | — | — | EP | disclosed |
| US-20190276471-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHOD OF THEIR USE | JANSSEN PHARMACEUTICA NV (BE) | 2019-09-12 | — | — | US | disclosed |
| US-20170283430-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHOD OF THEIR USE | JANSSEN PHARMACEUTICA NV (BE) | 2017-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10934310-B2 | Inhibitors of Bruton's tyrosine kinase and method of their use | ABL1, BTK, LYN | ALDH1A1 4036/4885GAA 1131/4885TSHR 3846/4885 |
| US-20170283430-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHOD OF THEIR USE | ABL1, BTK, LYN | ALDH1A1 4036/4885GAA 1131/4885TSHR 3846/4885 |
| US-20230097422-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHOD OF THEIR USE | ABL1, BTK, LYN | ALDH1A1 4036/4885GAA 1131/4885TSHR 3846/4885 |
| US-10717745-B2 | Inhibitors of Bruton's tyrosine kinase and method of their use | ABL1, BTK, LYN | ALDH1A1 4036/4885GAA 1131/4885TSHR 3846/4885 |
| US-20210101910-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHODS OF THEIR USE | ABL1, BTK, MYLK2 | ALDH1A1 3938/4885GAA 1257/4885TSHR 4089/4885 |
| US-20190276471-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHOD OF THEIR USE | ABL1, BTK, LYN | ALDH1A1 4036/4885GAA 1131/4885TSHR 3846/4885 |
| US-11319329-B2 | Inhibitors of Bruton's tyrosine kinase and methods of their use | ABL1, BTK, MYLK2 | ALDH1A1 3938/4885GAA 1257/4885TSHR 4089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.